|
Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma Clinical research trials and Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma. Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma clinical trial. Participants frequently get the best healthcare available for their Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma  Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma
Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma
For Condition: Melanoma
Status: Completed
Sponsor(s): Medarex ,
Synopsis: The objectives of this study are to determine the safety and activity profile of multiple doses of MDX-010, and to determine the whether the addition of cytotoxic chemotherapy (decarbazine [DTIC]) can augment the effects of MDX-010 in patients with chemotherapy naïve metastatic melanoma with a tolerable toxicity profile.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Clinical diagnosis of unresectable metastatic melanoma. - No prior chemotherapy for melanoma, and no chemotherapy for other malignancies within 5 years and at least 4 weeks since treatment (surgery, radiation, or immunotherapy) for melanoma. Exclusion Criteria Patients who exhibit any of the following conditions at screening will not be eligible for admission into the study: - Any other prior malignancy, except for the following: adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the patient has been disease-free for >=5 years. - Active autoimmune disease. - Active infection requiring therapy, or chronic active HBV or HCV, or confirmed reactivity with HIV tests.
Total Enrollment:
Location and Contact Information:
Northern California Melanoma Center
San Francisco, California, 94109
United States
Indiana Oncology/ Hematology Consultants
Indianapolis, Indiana, 46237
United States
Cancer Institute Medical Group
Santa Monica, California, 90404
United States
Joe Arrington Cancer. Research & Treatment Center
Lubbock, Texas, 79410
United States
Pacific Shores Medical Group
Long Beach, California, 90813
United States
Arizona Cancer Center
Tucson, Arizona, 85724
United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112
United States
Piedmont Oncology Specialists
Charlotte, North Carolina, 28207
United States
Additional Information:
Study ID Numbers: MDX010-08;
Study Start Date: October 2002
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050102
Other Melanoma Studies:
1. Treating Inoperable Lung Tumors With Heated Chemotherapy Medicine Delivered Solely to the Lung
2. Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
3. A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion with Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients with Locally Advanced Extremity Melanoma
4. CPG 7909 in Melanoma
5. Phase II Trial of Allovectin-7® for Metastatic Melanoma
Related Studies:
Other Melanoma Clinical Trials
Other Arizona Clinical Trials
Other Tucson Clinical Trials
Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma
|
|
|
|
|
|
|
|
